TY - JOUR
T1 - Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India-Multicentric, real-world study
AU - Singh, Deependra Vikram
AU - Agarwal, Aniruddha
AU - Goyal, Anubhav
AU - Shroff, Daraius
AU - Singh, Jatinder
AU - Kumar, Pradeep
AU - Reddy, Raja Rami
AU - Venkatesh, Ramesh
AU - Narnaware, Shilpi
AU - Joshi, Shrinivas
AU - Singh, Deependra V.
AU - Narula, Ritesh
AU - Joshi, Aishwarya
AU - Agarwal, Aniruddha
AU - Goyal, Anubhav
AU - Gupta, Charu
AU - Shroff, Daraius
AU - Anantharaman, Giridhar
AU - Singh, Jatinder
AU - Kumar, Pradeep
AU - Bawankule, Prashant
AU - Reddy, Raja Rami
AU - Jain, Rajiv
AU - Venkatesh, Ramesh
AU - Tiwari, Ruchir
AU - Sugumar, Shalini
AU - Gupta, Shashank Rai
AU - Narnaware, Shilpi
AU - Joshi, Shrinivas
AU - Choudhary, Somendra P.
N1 - Publisher Copyright:
© 2024 Indian Journal of Ophthalmology.
PY - 2024/12
Y1 - 2024/12
N2 - Purpose: To evaluate the anatomic and visual outcomes and safety profile of initial Indian eyes with neovascular age-related macular degeneration (nAMD) treated with intravitreal injection (IVI) of brolucizumab. Methods: This retrospective multicentric, real-world study enrolled consecutive eyes with nAMD that were treated with IVI brolucizumab after it was launched in India in October 2020. Data collected for each eye included best-corrected visual acuity (BCVA), central subfield thickness (CSFT), subretinal fluid (SRF), and intraretinal fluid (IRF) status at 6, 12, and 24 months follow-up. Also recorded were the lens status, treatment protocol, number of injections received before enrollment (in switch-over cases), total number of injections, and adverse effects noticed during the study period. Primary outcomes were change in BCVA, CSFT at follow-up visits, and incidence of intraocular inflammation (IOI). Secondary outcomes were profile of macular neovascularization, treatment protocols, mean number of injections, and maximum injection-free interval observed in eyes treated by pro-re-nata (PRN) protocol. Results: In total, 331 eyes received a mean of 3.55 ± 1.83 injections. Most frequent treatment protocol was PRN (53%). BCVA data was available for 100%, 96%, and 74% eyes at 6, 12, and 24 months follow-up. BCVA and CSFT improved significantly (P < 0.001) at all follow-ups. Two hundred and seventy-six (83.38%) out of 331 eyes received more than one injection; out of these, 241 (87.3%) eyes that were treated by PRN protocol could achieve mean 'maximum injection-free interval' of 19.43 ± 8.82 weeks. IOI and retinal vasculitis were reported in 2.11% (7/331) and 0.60% (2/331) eyes, respectively. None of the eyes with IOI or vasculitis lost any vision at the final follow-up. Conclusion: This study demonstrated favorable visual and anatomic outcomes and safety profile for eyes with nAMD treated by IVI brolucizumab. Mean maximum injection-free interval in eyes treated with PRN was 19 weeks.
AB - Purpose: To evaluate the anatomic and visual outcomes and safety profile of initial Indian eyes with neovascular age-related macular degeneration (nAMD) treated with intravitreal injection (IVI) of brolucizumab. Methods: This retrospective multicentric, real-world study enrolled consecutive eyes with nAMD that were treated with IVI brolucizumab after it was launched in India in October 2020. Data collected for each eye included best-corrected visual acuity (BCVA), central subfield thickness (CSFT), subretinal fluid (SRF), and intraretinal fluid (IRF) status at 6, 12, and 24 months follow-up. Also recorded were the lens status, treatment protocol, number of injections received before enrollment (in switch-over cases), total number of injections, and adverse effects noticed during the study period. Primary outcomes were change in BCVA, CSFT at follow-up visits, and incidence of intraocular inflammation (IOI). Secondary outcomes were profile of macular neovascularization, treatment protocols, mean number of injections, and maximum injection-free interval observed in eyes treated by pro-re-nata (PRN) protocol. Results: In total, 331 eyes received a mean of 3.55 ± 1.83 injections. Most frequent treatment protocol was PRN (53%). BCVA data was available for 100%, 96%, and 74% eyes at 6, 12, and 24 months follow-up. BCVA and CSFT improved significantly (P < 0.001) at all follow-ups. Two hundred and seventy-six (83.38%) out of 331 eyes received more than one injection; out of these, 241 (87.3%) eyes that were treated by PRN protocol could achieve mean 'maximum injection-free interval' of 19.43 ± 8.82 weeks. IOI and retinal vasculitis were reported in 2.11% (7/331) and 0.60% (2/331) eyes, respectively. None of the eyes with IOI or vasculitis lost any vision at the final follow-up. Conclusion: This study demonstrated favorable visual and anatomic outcomes and safety profile for eyes with nAMD treated by IVI brolucizumab. Mean maximum injection-free interval in eyes treated with PRN was 19 weeks.
KW - Brolucizumab
KW - neovascular AMD
KW - vascular endothelial growth factor
UR - https://www.scopus.com/pages/publications/85211414954
U2 - 10.4103/IJO.IJO_757_24
DO - 10.4103/IJO.IJO_757_24
M3 - Article
C2 - 39620667
AN - SCOPUS:85211414954
SN - 0301-4738
VL - 72
SP - 1786
EP - 1794
JO - Indian Journal of Ophthalmology
JF - Indian Journal of Ophthalmology
IS - 12
ER -